Success Stories: NIW Approved for Bioengineering Researcher Advancing Virus‑Based Cancer Therapeutics

Posted by wegreened on January 30, 2026 in NIW, Technology (Nanotechnology, Nanoscience, Biomaterials, Biomechanics, Biomedical Engineering, Bioinformatics, Bioengineering, Biomedical Science, Biotechnologies)

Client’s Testimonial:

“I really appreciated all the help and support from NAILG in my journey of NIW filing. They made the process incredibly smooth and easy for me. They were thorough, professional, and always quick to respond to my questions and organize my documents, craft a compelling petition, and provide detailed guidance every step of the way. I highly recommend their services to anyone.”

On February 7^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Bioengineering (Approval Notice).

General Field: Bioengineering Position at the Time of Case Filing: Postdoctoral Researcher Country of Origin: China State of Residence at the Time of Filing: California Approval Notice Date: February 7^th, 2025 Processing Time: 1 year, 3 months, 5 days

Case Summary: We are pleased to share the success story of an EB‑2 NIW approval for a postdoctoral researcher from China whose work on virus‑based cancer therapeutics has both substantial merit and national importance. At filing, the client was conducting advanced bioengineering research at a leading U.S. institution and had already built a strong record of high‑impact publications and peer-reviewed service. Research Focus and Contributions: The petition detailed the client’s innovative program, which includes:

Engineering oncolytic viruses that selectively replicate in and kill cancer cells
Applying synthetic biology and protein‑engineering tools to optimize viral delivery systems
Developing novel assays for evaluating therapeutic efficacy and safety in preclinical models

Research Impact and Metrics: To demonstrate the national interest and unique qualifications, the petition highlighted:

5 peer‑reviewed journal articles, 1 preprint, and 1 patent application
375 citations reflecting widespread adoption of her methods in molecular biology and genetics research
4 highly ranked peer-reviewed journals

These metrics, together with expert testimonials, underscored the client’s original contributions of major significance and her capacity to advance critical cancer‑therapeutic technologies. Here is a compelling excerpt from one of the recommendation letters that highlights how the client’s research benefits the United States:

“[Client’s] engineered a protein-based system that selectively recognized and entered tumor cells with specific mutations. In preclinical models, this system replicated within the cancer cells and significantly extended survival compared to standard chemotherapy.”

Demonstrating Substantial Merit & National Importance Evidence showed that virus‑based cancer therapies address urgent public‑health needs by improving treatment specificity, reducing side effects, and lowering overall healthcare costs. Experts noted the client’s work aligns with national priorities for innovative cancer treatments and emerging biotechnologies. Well Positioned to Advance the Proposed Endeavor Our submission detailed the client’s rigorous academic and research pedigree, holding a master’s degree in bioengineering, followed by intensive postdoctoral training in viral vector design and her current role leading preclinical evaluation of oncolytic candidates. We highlighted her track record of securing competitive grants and collaborating with multidisciplinary teams to translate bench‑top discoveries into viable therapeutic platforms. Letters from independent authorities praised her ability to integrate synthetic biology, immunology, and nanoscale delivery methods to push the field forward. This multifaceted evidence demonstrated that she possesses both the technical expertise and the professional network required to drive continued breakthroughs in virus‑based cancer therapeutics. Approval and Outcome Filed November 2, 2023, and approved February 7, 2025, in just 1 year, 3 months, 5 days, the NIW approval affirms the United States’ interest in securing the client’s extraordinary contributions. NAILG is proud to have guided this client through a successful NIW process and looks forward to her ongoing impact in bioengineering and cancer therapeutics.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With nearly 64,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 64,000 in 2025.

Track Record of Success EB-1 and NIW Approvals

(2020.01 - 2024.12)

Category	Approval or Refund^®		Approval or Refiling^TM
Category	Approved Sum	Success Rate	Approved Sum	Success Rate
NIW	28,946	99.52%	3,030	98.31%
EB1A	4,322	91.76%	2,870	88.91%
EB1B	793	98.51%	236	90.77%
Total	34,061	98.44%	6,136	93.39%